5.1x00a0;Application of the approach described within this guide is intended to satisfy international regulatory expectations in ensuring that manufacturing systems and equipment are fit for intended use, and to satisfy requirements for design, installation, operation, and performance.
5.2x00a0;The approach described in this guide applies concepts and principles introduced in the FDA initiative, Pharmaceutical cGMPs for the 21st Centuryx2014;A Risk-Based Approach.
5.3x00a0;This guide supports, and is consistent with, the framework described in ICH Q8, ICH Q9, ICH Q10, and ICH Q11.
5.4x00a0;This guide may be used independently or in conjunction with other E55 standards published by ASTM International.
1.1x00a0;This guide is applicable to all elements of pharmaceutical and biopharmaceutical manufacturing systems including: facility equipment, process equipment, supporting utilities, associated process monitoring and control systems, and automation systems that have the potential to affect product quality and patient safety.
1.2x00a0;For brevity, these are referred to throughout the rest of this guide as manufacturing systems.
1.3x00a0;This guide may also be applied to laboratory, information, and medical device manufacturing systems.
1.4x00a0;This guide is applicable to both new and existing manufacturing systems. The approach may be used for the implementation of changes to existing systems, and their continuous improvement during operation.
1.5x00a0;This guide is applicable throughout the life-cycle of the manufacturing system from concept to retirement.
1.6x00a0;This standard does not address employee health and safety, environmental, or other non-GxP regulations. This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
工业4.0和生物制药连续生产 全球一次性概念和可重组模块化工厂设计的关键因素 传统不锈钢设备与一次性系统的成本效率对比 “一次性使用系统”浸出物和可提取物研究及本土化验证服务 AI,集成数据,虚拟建模完善生物制造工艺与质量控制 QbD的DoE策略 (分会场B) 最新合同外包模式及生物制药研发: MAH制度下的合同生产的商业模式的探讨 药企应采取哪些关键方法来与外部供应链网络的更好融合...
生物洁净技术论坛 国内&欧美生物制药洁净材料工艺创新及新技术动向,多位资深知名专家一对一交流机会 洁净厂房设计、验证与项目管理培训 洁净室项目管理全过程的相关法规、指南、检查指导、达标方针等标准及新厂建设实操讲解 医药洁净领域设计与工程创新论坛 医药工业洁净厂房设计标准关键起草人宣讲,权威答疑互动 工厂参观——“洁净室系统解决方案”线路 趣味与实用相结合,亲身体验供应商的制造技术...
我们与上一代DSC系统的用户密切合作,确保MicroCal PEAQ-DSC在生物制药开发周期中支持广泛的需求。随着生物制药的重要性不断增长,我们看到客户正在寻找强大的分析系统,可以提供真正为开发,制定和过程决策提供信息的数据,以及支持监管挑战。 DSC长期以来一直被认为是稳定性测量的黄金标准,但现在,使用新的MicroCal PEAQ-DSC,我们相信我们已经重新定义了这种技术的可能性。”...
Copyright ©2007-2022 ANTPEDIA, All Rights Reserved
京ICP备07018254号 京公网安备1101085018 电信与信息服务业务经营许可证:京ICP证110310号